Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)

Experimental Cell Research

Volumn 314, Issue 5, 2008, Pages 1082-1093

  Hecht, Monica ^a   von Metzler, Ivana ^a   Sack, Katja ^a   Kaiser, Martin ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bone; Cell signalling; Cell cell interaction; Matrix metalloproteinase; Multiple myeloma; Osteoclast; Plasmin

Indexed keywords

CATHEPSIN K; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTROPHIL COLLAGENASE; PROTEIN KINASE B; STAT3 PROTEIN; STROMELYSIN; UROKINASE;

ARTICLE; BONE DEFECT; CELL GROWTH; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR GROWTH; UPREGULATION;

EID: 39449098165     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.10.021     Document Type: Article

References (34)

1. Yaccoby S., Wezeman M.J., Henderson A., Cottler-Fox M., Yi Q., Barlogie B., and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 64 (2004) 2016-2023
2. Roodman G.D. New potential targets for treating myeloma bone disease. Clin. Cancer Res. 12 (2006) 6270-6273
3. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
4. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., Findlay D.M., Bardy P., and Zannettino A.C. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 63 (2003) 5438-5445
5. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
6. Sezer O., Heider U., Zavrski I., Kuhne C.A., and Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101 (2003) 2094-2098
7. Terpos E., Szydlo R., Apperley J.F., Hatjiharissi E., Politou M., Meletis J., Viniou N., Yataganas X., Goldman J.M., and Rahemtulla A. Soluble receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a Novel Prognostic Index. Blood 102 (2003) 1064-1069
8. Everts V., Delaisse J.M., Korper W., Niehof A., Vaes G., and Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J. Cell. Physiol. 150 (1992) 221-231
9. Delaisse J.M., Andersen T.L., Engsig M.T., Henriksen K., Troen T., and Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. (2003) 504-513
10. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., Ferreras Foged N.T., Delmas P.D., and Delaisse J.M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 273 (1998) 32347-32352
11. Daci E., Udagawa N., Martin T.J., Bouillon R., and Carmeliet G. The role of the plasminogen system in bone resorption in vitro. J. Bone Miner. Res. 14 (1999) 946-952
12. Tumber A., Papaioannou S., Breckon J., Meikle M.C., Reynolds J.J., and Hill P.A. The effects of serine proteinase inhibitors on bone resorption in vitro. J. Endocrinol. 178 (2003) 437-447
13. Bruno B., Giaccone L., Rotta M., Anderson K., and Boccadoro M. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 19 (2005) 1729-1738
14. Abe M., Kenji H., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., Kido S., Oshima T., Shibata H., Ozaki S., Inoue D., and Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104 (2004) 2484-2491
15. von Metzler I., Krebbel H., Hecht M., Fleissner C., Mieth M., Kaiser M., Jakob C., Sterz J., Kleeberg L., Heider U., and Sezer O. Bortezomib inhibits human osteoclastogenesis. Leukemia 21 (2007) 2025-2034
16. Hecht M., Papoutsi M., Tran H.D., Wilting J., and Schweigerer L. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res. 64 (2004) 6109-6118
17. Susa M., Luong-Nguyen N.H., Cappellen D., Zamurovic N., and Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J. Transl. Med. 2 (2004) 6
18. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M.J., Blacklock H.A., Bell R., Simeone J., Reitsma D.J., Heffernan M., Seaman J., and Knight R.D. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334 (1996) 488-493
19. Chatterjee M., Stühmer T., Herrmann P., Bommert K., and Bargou R.C. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104 (2004) 3712-3721
20. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nuarez G., Dalton W.S., and Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
21. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
22. Grassi F., Cristino S., Toneguzzi S., Piacentini A., Facchini A., and Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J. Cell. Physiol. 199 (2004) 244-251
23. Daci E., Everts V., Torrekens S., Van Herck E., Tigchelaar-Gutterr W., Bouillon R., and Carmeliet G. Increased bone formation in mice lacking plasminogen activators. J. Bone Miner. Res. 18 (2003) 1167-1176
24. Kahari V.M., and Saarialho-Kere U. Matrix metalloproteinases in skin. Exp. Dermatol. 6 (1997) 199-213
25. Everts V., Korper W., Hoeben K.A., Jansen I.D., Bromme D., Cleutjens K.B., Heeneman S., Peters C., Reinheckel T., Saftig P., and Beertsen W. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J. Bone Miner. Res. 21 (2006) 1399-1408
26. Ishibashi O., Niwa S., Kadoyama K., and Inui T. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci. 79 (2006) 1657-1660
27. Leloup G., Delaisse J.M., and Vaes G. Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. J. Bone Miner. Res. 9 (1994) 891-902
28. Delaisse J.M., Engsig M.T., Everts V., del Carmen Ovejero M., Ferreras M., Lund L., Vu T.H., Werb Z., Winding B., Lochter A., Karsdal M.A., Troen T., Kirkegaard T., Lenhard T., Heegaard A.M., Neff L., Baron R., and Foged N.T. Proteinases in bone resorption: obvious and less obvious roles. Clin. Chim. Acta 291 (2000) 223-234
29. Lalou C., Silve C., Rosato R., Segovia B., and Binoux M. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135 (1994) 2318-2326
30. Van Valckenborgh E., Croucher P.I., De Raeve H., Carron C., De Leenheer E., Blacher S., Devy L., Noal A., De Bruyne E., Asosingh K., Van Riet I., Van Camp B., and Vanderkerken K. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am. J. Pathol. 165 (2004) 869-878
31. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13 (1999) 781-792
32. Nguyen A.N., Stebbins E.G., Henson M., O'Young G., Choi S.J., Quon D., Damm D., Reddy M., Ma J.Y., Haghnazari E., Kapoun A.M., Medicherla S., Protter A., Schreiner G.F., Kurihara N., Anderson J., Roodman G.D., Navas T.A., and Higgins L.S. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp. Cell Res. 312 (2006) 1909-1923
33. Smola-Hess S., Pahne J., Mauch C., Zigrino P., Smola H., and Pfister H.J. Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J. Gen. Virol. 86 (2005) 1291-1296
34. Tsareva S.A., Moriggl R., Corvinus F.M., Wiederanders B., Schutz A., Kovacic B., and Friedrich K. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 9 (2007) 279-291